Pacira | PCRX

Stock Price
39.09
Daily Change
2.76%
Yearly
-39.22%
Q2 Forecast
38.32
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Astellas Pharma 2,229.00 -7.00 -0.31% 9.83%
AmerisourceBergen 174.52 1.93 1.12% 18.70%
Bristol-Myers Squibb 65.66 0.98 1.52% -12.65%
Cara Therapeutics 3.09 0 0% -64.97%
Coherus Biosciences 4.45 0.40 9.88% -41.22%
Depomed 6.35 -0.08 -1.24% 99.06%
Endo International 0.03 0 0% -94.89%
Heron Therapeutics 1.12 0.01 0.90% -62.67%
Horizon Pharma 99.93 -0.47 -0.47% 9.46%
Ironwood Pharmaceuticals 11.03 0.15 1.38% -2.22%
J&J 156.97 2.43 1.57% -11.02%
Ligand Pharmaceuticals 75.31 4.11 5.77% -11.32%
Nektar Therapeutics 0.62 0.02 3.08% -82.94%
Omeros 7.41 0.13 1.79% 196.40%
Pacira 39.09 1.05 2.76% -39.22%
Pfizer 38.36 0.34 0.89% -27.89%
Perrigo 32.99 0.93 2.90% -16.18%
Revance Therapeutics 31.06 0.65 2.14% 133.53%
Supernus Pharmaceuticals 33.53 0.57 1.73% 18.56%
Teva Pharmaceutical Industries 2,743.00 63.00 2.35% -12.78%
Xeris Pharmaceuticals 2.82 0.20 7.63% 28.18%
Xoma 17.97 0.96 5.64% -2.28%
Zoetis 171.88 5.88 3.54% 1.70%

Indexes Price Day Year
USND 13241 139.78 1.07% 10.22%
US2000 1831 62.97 3.56% -2.77%

Pacira

Pacira Pharmaceuticals traded at $39.09 this Friday June 2nd, increasing $1.05 or 2.76 percent since the previous trading session. Looking back, over the last four weeks, Pacira gained 9.35 percent. Over the last 12 months, its price fell by 39.22 percent. Looking ahead, we forecast Pacira Pharmaceuticals to be priced at 38.32 by the end of this quarter and at 35.11 in one year, according to Trading Economics global macro models projections and analysts expectations.

Pacira BioSciences, Inc. is the holding company of Pacira Pharmaceuticals, Inc. The Company is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its other product candidate, the iovera system is a non-opioid handheld cryoanalgesia device used to produce precise, controlled doses of cold temperature only to targeted nerves. The iovera system is complementary to EXPAREL as a non-opioid therapy that alleviates pain using a non-pharmacological nerve block to disrupt pain signals being transmitted to the brain from the site of injury or surgery.